These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12769792)

  • 1. Particle-based vaccines for HIV-1 infection.
    Young KR; Ross TM
    Curr Drug Targets Infect Disord; 2003 Jun; 3(2):151-69. PubMed ID: 12769792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virus-like particles: designing an effective AIDS vaccine.
    Young KR; McBurney SP; Karkhanis LU; Ross TM
    Methods; 2006 Sep; 40(1):98-117. PubMed ID: 16997718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions.
    Virnik K; Ni Y; Berkower I
    Vaccine; 2013 Apr; 31(17):2119-25. PubMed ID: 23474312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus-like particles activate multiple types of immune cells.
    Sailaja G; Skountzou I; Quan FS; Compans RW; Kang SM
    Virology; 2007 Jun; 362(2):331-41. PubMed ID: 17276476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in the development of an HIV-1 vaccine.
    Letvin NL
    Science; 1998 Jun; 280(5371):1875-80. PubMed ID: 9632379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication-defective HIV as a vaccine candidate.
    Tung FY; Rinaldo CR; Montelaro RC
    AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1247-52. PubMed ID: 9764908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.
    Meador LR; Kessans SA; Kilbourne J; Kibler KV; Pantaleo G; Roderiguez ME; Blattman JN; Jacobs BL; Mor TS
    Virology; 2017 Jul; 507():242-256. PubMed ID: 28458036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and virulence of attenuated vaccinia virus Tian Tan encoding HIV-1 muti-epitope genes, p24 and cholera toxin B subunit in mice.
    Du S; Wang Y; Liu C; Wang M; Zhu Y; Tan P; Ren D; Li X; Tian M; Yin R; Li C; Jin N
    J Virol Methods; 2015 Jul; 219():1-9. PubMed ID: 25796990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.
    Das AT; Zhou X; Vink M; Klaver B; Berkhout B
    Expert Rev Vaccines; 2002 Oct; 1(3):293-301. PubMed ID: 12901570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live attenuated AIDS viruses as vaccines: promise or peril?
    Ruprecht RM
    Immunol Rev; 1999 Aug; 170():135-49. PubMed ID: 10566148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel non-integrative single-cycle chimeric HIV lentivector DNA vaccine.
    Moussa M; Arrode-Brusés G; Manoylov I; Malogolovkin A; Mompelat D; Ishimwe H; Smaoune A; Ouzrout B; Gagnon J; Chebloune Y
    Vaccine; 2015 May; 33(19):2273-2282. PubMed ID: 25825333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus-1 vaccine design: where do we go now?
    Wijesundara DK; Jackson RJ; Ramshaw IA; Ranasinghe C
    Immunol Cell Biol; 2011 Mar; 89(3):367-74. PubMed ID: 20956986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.